CN104470525A - Janus激酶(jak)抑制剂的给药方案 - Google Patents
Janus激酶(jak)抑制剂的给药方案 Download PDFInfo
- Publication number
- CN104470525A CN104470525A CN201380038563.3A CN201380038563A CN104470525A CN 104470525 A CN104470525 A CN 104470525A CN 201380038563 A CN201380038563 A CN 201380038563A CN 104470525 A CN104470525 A CN 104470525A
- Authority
- CN
- China
- Prior art keywords
- administration
- effective dose
- treatment
- jak
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810369706.3A CN108354938A (zh) | 2012-07-20 | 2013-07-18 | Janus激酶(jak)抑制剂的给药方案 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261674289P | 2012-07-20 | 2012-07-20 | |
US61/674,289 | 2012-07-20 | ||
US201361815803P | 2013-04-25 | 2013-04-25 | |
US61/815,803 | 2013-04-25 | ||
PCT/US2013/051015 WO2014015107A1 (en) | 2012-07-20 | 2013-07-18 | Dosing regimen for janus kinase (jak) inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810369706.3A Division CN108354938A (zh) | 2012-07-20 | 2013-07-18 | Janus激酶(jak)抑制剂的给药方案 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104470525A true CN104470525A (zh) | 2015-03-25 |
Family
ID=48901189
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810369706.3A Pending CN108354938A (zh) | 2012-07-20 | 2013-07-18 | Janus激酶(jak)抑制剂的给药方案 |
CN201380038563.3A Pending CN104470525A (zh) | 2012-07-20 | 2013-07-18 | Janus激酶(jak)抑制剂的给药方案 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810369706.3A Pending CN108354938A (zh) | 2012-07-20 | 2013-07-18 | Janus激酶(jak)抑制剂的给药方案 |
Country Status (24)
Country | Link |
---|---|
US (1) | US9522151B2 (zh) |
EP (1) | EP2874630B1 (zh) |
JP (2) | JP6022063B2 (zh) |
KR (2) | KR20150028299A (zh) |
CN (2) | CN108354938A (zh) |
AU (1) | AU2013292547B2 (zh) |
BR (1) | BR112015000808A2 (zh) |
CA (1) | CA2878867C (zh) |
CY (1) | CY1121436T1 (zh) |
DK (1) | DK2874630T3 (zh) |
ES (1) | ES2707627T3 (zh) |
HK (2) | HK1209314A1 (zh) |
HR (1) | HRP20182088T1 (zh) |
HU (1) | HUE042771T2 (zh) |
IN (1) | IN2015DN00370A (zh) |
LT (1) | LT2874630T (zh) |
MX (1) | MX360857B (zh) |
NZ (1) | NZ703152A (zh) |
PL (1) | PL2874630T3 (zh) |
PT (1) | PT2874630T (zh) |
RS (1) | RS58242B1 (zh) |
SI (1) | SI2874630T1 (zh) |
WO (1) | WO2014015107A1 (zh) |
ZA (1) | ZA201500134B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2958921T3 (pl) | 2013-02-22 | 2018-01-31 | Pfizer | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinaz janusowych (jak) |
WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
MX2018004605A (es) | 2015-10-16 | 2018-11-29 | Abbvie Inc | Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma. |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
JP7096592B2 (ja) * | 2016-02-16 | 2022-07-06 | ワシントン・ユニバーシティ | Jak阻害剤およびこれらの利用 |
CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
BR112021014525A8 (pt) * | 2019-01-30 | 2022-11-22 | Gargamel Zhuhai Biotech Ltd | Inibidor de jak e método de preparação do mesmo |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
CA3201608A1 (en) | 2020-12-18 | 2022-06-23 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020019526A1 (en) * | 1998-06-19 | 2002-02-14 | Blumenkopf Todd A. | Pyrrolo[2,3-d]pyrimidine compounds |
WO2010020905A1 (en) * | 2008-08-20 | 2010-02-25 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
-
2013
- 2013-07-18 IN IN370DEN2015 patent/IN2015DN00370A/en unknown
- 2013-07-18 ES ES13742573T patent/ES2707627T3/es active Active
- 2013-07-18 EP EP13742573.2A patent/EP2874630B1/en not_active Revoked
- 2013-07-18 RS RS20190051A patent/RS58242B1/sr unknown
- 2013-07-18 MX MX2015000871A patent/MX360857B/es active IP Right Grant
- 2013-07-18 KR KR1020157001085A patent/KR20150028299A/ko active Application Filing
- 2013-07-18 CN CN201810369706.3A patent/CN108354938A/zh active Pending
- 2013-07-18 HU HUE13742573A patent/HUE042771T2/hu unknown
- 2013-07-18 SI SI201331328T patent/SI2874630T1/sl unknown
- 2013-07-18 US US14/415,047 patent/US9522151B2/en active Active
- 2013-07-18 NZ NZ703152A patent/NZ703152A/en unknown
- 2013-07-18 CA CA2878867A patent/CA2878867C/en active Active
- 2013-07-18 DK DK13742573.2T patent/DK2874630T3/en active
- 2013-07-18 BR BR112015000808A patent/BR112015000808A2/pt not_active Application Discontinuation
- 2013-07-18 KR KR1020177007913A patent/KR20170034949A/ko not_active Application Discontinuation
- 2013-07-18 JP JP2015523243A patent/JP6022063B2/ja active Active
- 2013-07-18 AU AU2013292547A patent/AU2013292547B2/en active Active
- 2013-07-18 CN CN201380038563.3A patent/CN104470525A/zh active Pending
- 2013-07-18 WO PCT/US2013/051015 patent/WO2014015107A1/en active Application Filing
- 2013-07-18 PT PT13742573T patent/PT2874630T/pt unknown
- 2013-07-18 LT LTEP13742573.2T patent/LT2874630T/lt unknown
- 2013-07-18 PL PL13742573T patent/PL2874630T3/pl unknown
-
2015
- 2015-01-08 ZA ZA2015/00134A patent/ZA201500134B/en unknown
- 2015-09-24 HK HK15109423.1A patent/HK1209314A1/zh unknown
-
2016
- 2016-08-05 JP JP2016154135A patent/JP2017019816A/ja active Pending
-
2018
- 2018-08-23 HK HK18110906.2A patent/HK1252083A1/zh unknown
- 2018-12-10 HR HRP20182088TT patent/HRP20182088T1/hr unknown
-
2019
- 2019-02-14 CY CY20191100203T patent/CY1121436T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020019526A1 (en) * | 1998-06-19 | 2002-02-14 | Blumenkopf Todd A. | Pyrrolo[2,3-d]pyrimidine compounds |
WO2010020905A1 (en) * | 2008-08-20 | 2010-02-25 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
Also Published As
Publication number | Publication date |
---|---|
JP2015522620A (ja) | 2015-08-06 |
LT2874630T (lt) | 2019-02-11 |
HUE042771T2 (hu) | 2019-07-29 |
NZ703152A (en) | 2016-03-31 |
PT2874630T (pt) | 2019-01-31 |
IN2015DN00370A (zh) | 2015-06-12 |
US9522151B2 (en) | 2016-12-20 |
US20150126535A1 (en) | 2015-05-07 |
HK1209314A1 (zh) | 2016-04-01 |
MX360857B (es) | 2018-11-20 |
AU2013292547A1 (en) | 2015-01-22 |
CN108354938A (zh) | 2018-08-03 |
KR20170034949A (ko) | 2017-03-29 |
RS58242B1 (sr) | 2019-03-29 |
ZA201500134B (en) | 2016-08-31 |
AU2013292547B2 (en) | 2017-05-04 |
SI2874630T1 (sl) | 2019-04-30 |
PL2874630T3 (pl) | 2019-04-30 |
ES2707627T3 (es) | 2019-04-04 |
CA2878867A1 (en) | 2014-01-23 |
HK1252083A1 (zh) | 2019-05-17 |
DK2874630T3 (en) | 2019-01-28 |
KR20150028299A (ko) | 2015-03-13 |
JP6022063B2 (ja) | 2016-11-09 |
MX2015000871A (es) | 2015-05-07 |
HRP20182088T1 (hr) | 2019-02-08 |
EP2874630A1 (en) | 2015-05-27 |
JP2017019816A (ja) | 2017-01-26 |
BR112015000808A2 (pt) | 2017-06-27 |
EP2874630B1 (en) | 2018-12-05 |
WO2014015107A1 (en) | 2014-01-23 |
CA2878867C (en) | 2018-01-09 |
CY1121436T1 (el) | 2020-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104470525A (zh) | Janus激酶(jak)抑制剂的给药方案 | |
US10821109B1 (en) | Pyrazine-containing compound | |
US20110311476A1 (en) | Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation | |
TWI835050B (zh) | 一種吡啶并[1,2-a]嘧啶酮類似物的應用 | |
Sokolova et al. | Toxicological evaluation of a new iron-containing preparation for farm animals with alimentary anemia | |
JP2024516302A (ja) | 結節性痒疹を治療するためのjak1経路阻害薬 | |
CN103547289A (zh) | 治疗阿尔茨海默氏病的方法和组合物 | |
US9662305B2 (en) | Use of bucillamine in the treatment of gout | |
CN101380317A (zh) | 减缓搔痒症的药学组合物 | |
WO2022007982A2 (zh) | 一种药物组合物及其应用 | |
WO2015055974A1 (en) | Proton pump inhibitor paste compositions | |
US20160113955A1 (en) | Compositions And Methods For Immunotherapy | |
CN113082025B (zh) | 二羟基苯甲酰胺衍生物在制备SerC抑制剂和抗结核药物中的应用 | |
US20240252469A1 (en) | Carnosine Analogs for Use in the Treatment of Metabolic Disorders | |
CA3097722C (en) | Methods and compositions for the treatment of multiple sclerosis | |
US8501242B2 (en) | Methods and compositions for treating neoplasia | |
CN118541364A (zh) | 氨基吡唑化合物的用途 | |
CN118356493A (zh) | Pdk1蛋白或其编码基因作为靶点在制备治疗系统性红斑狼疮药物中的应用 | |
CN103755562B (zh) | 一种洛伐他汀羟基酸化物的制备方法、组合物、组合物的制备方法及其应用 | |
US20190388450A1 (en) | Compositions And Methods For Immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151014 Address after: American New Jersey Applicant after: ZOETIS LLC Address before: American New Jersey Applicant before: Shuoteng Co., Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1209314 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |
|
RJ01 | Rejection of invention patent application after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1209314 Country of ref document: HK |